These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 10746786)
1. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Luiten R; van der Bruggen P Tissue Antigens; 2000 Feb; 55(2):149-52. PubMed ID: 10746786 [TBL] [Abstract][Full Text] [Related]
2. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Luiten RM; Demotte N; Tine J; van der Bruggen P Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359 [TBL] [Abstract][Full Text] [Related]
3. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041 [TBL] [Abstract][Full Text] [Related]
4. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345 [TBL] [Abstract][Full Text] [Related]
5. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782 [TBL] [Abstract][Full Text] [Related]
6. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Schultz ES; Zhang Y; Knowles R; Tine J; Traversari C; Boon T; van der Bruggen P Tissue Antigens; 2001 Feb; 57(2):103-9. PubMed ID: 11260504 [TBL] [Abstract][Full Text] [Related]
7. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204 [TBL] [Abstract][Full Text] [Related]
8. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors. Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676 [TBL] [Abstract][Full Text] [Related]
9. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Kobayashi T; Lonchay C; Colau D; Demotte N; Boon T; van der Bruggen P Tissue Antigens; 2003 Nov; 62(5):426-32. PubMed ID: 14617050 [TBL] [Abstract][Full Text] [Related]
10. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Zhang Y; Stroobant V; Russo V; Boon T; van der Bruggen P Tissue Antigens; 2002 Nov; 60(5):365-71. PubMed ID: 12492812 [TBL] [Abstract][Full Text] [Related]
11. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691 [TBL] [Abstract][Full Text] [Related]
12. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290 [TBL] [Abstract][Full Text] [Related]
13. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853 [TBL] [Abstract][Full Text] [Related]
14. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules. Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408 [TBL] [Abstract][Full Text] [Related]
15. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731 [TBL] [Abstract][Full Text] [Related]
16. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150 [TBL] [Abstract][Full Text] [Related]
17. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953 [TBL] [Abstract][Full Text] [Related]
18. A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells. Chaux P; Lethé B; Van Snick J; Corthals J; Schultz ES; Cambiaso CL; Boon T; van der Bruggen P Eur J Immunol; 2001 Jun; 31(6):1910-6. PubMed ID: 11433388 [TBL] [Abstract][Full Text] [Related]
19. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307 [TBL] [Abstract][Full Text] [Related]
20. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Bilsborough J; Panichelli C; Duffour MT; Warnier G; Lurquin C; Schultz ES; Thielemans K; Corthals J; Boon T; van der Bruggen P Tissue Antigens; 2002 Jul; 60(1):16-24. PubMed ID: 12366779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]